Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Hospital Admissions Not Related to COVID-19 Fell in Early 2020
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Non-COVID-19 hospital admissions decreased considerably with the onset of COVID-19, with declines generally similar across patient demographic subgroups from February to April 2020, according to a report published online Sept. 24 in Health Affairs.
Thousands of Donated Corneas From Gay, Bisexual Men Rejected
TUESDAY, Sept. 29, 2020 (HealthDay News) — An estimated 1,558 to 3,217 corneal donations were disqualified in 2018 because of federal regulations prohibiting corneal donation by men who have sex with men (MSM), according to a study published online Sept. 24 in JAMA Ophthalmology.
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
Pupillary Light Reflex Metrics May ID Sports Concussion in Teens
FRIDAY, Sept. 25, 2020 (HealthDay News) — Several pupillary light reflex (PLR) metrics are increased for adolescents with concussion versus healthy controls, according to a study published online Sept. 24 in JAMA Ophthalmology.
Lower Proportion of Inpatients With COVID-19 Wear Glasses
FRIDAY, Sept. 18, 2020 (HealthDay News) — The proportion of inpatients with COVID-19 who wear eyeglasses for extended daily periods is lower than in the general population, according to a study published online Sept. 16 in JAMA Ophthalmology.
Pediatric Ophthalmologists Hit Hard Financially by COVID-19
TUESDAY, Sept. 15, 2020 (HealthDay News) — Pediatric ophthalmologists are financially struggling as a result of the COVID-19 pandemic, according to research recently published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus.
Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 (HealthDay News) — Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine.
Widespread Avoidance of Medical Care Found Due to COVID-19 Concerns